Physician profile
William Sanders
NPI 1093921066
$16,378.74
in general payments reported to CMS, 2019-2025
66 companies · $3,137 in 2025
The $3,137 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,611 · 2020: $1,173 · 2021: $1,831 · 2022: $2,222 · 2023: $3,167 · 2024: $3,238 · 2025: $3,137.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,534 · Education: $8.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,534.47 |
| Education | $8.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,899.26 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $1,412.03 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $1,277.58 | 2019-2025 | Trintellix |
| Lilly USA, LLC | $1,197.35 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $917.63 | 2022-2025 | |
| Pfizer INC. | $847.32 | 2019-2025 | |
| Amgen INC. | $758.09 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $743.53 | 2019-2025 | Ofev, Jardiance, Synjardy |
| Acadia Pharmaceuticals INC | $627.97 | 2023-2025 | Nuplazid |
| Glaxosmithkline, LLC. | $582.74 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $564.52 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Merck Sharp & Dohme LLC | $533.47 | 2019-2025 | Gardasil 9, Vaxneuvance, Belsomra |
| Astellas Pharma US INC | $399.77 | 2019-2025 | Veozah, Myrbetriq |
| Lundbeck LLC | $387.98 | 2022-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $334.78 | 2019-2024 | Xifaxan |
Show all 66 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Sanders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.